Vimarsana
Biggest News Aggregation in the World

Silvia Comis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Silvia Comis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Silvia Comis Today - Breaking & Trending Today

OSE Immunotherapeutics Presents First Positive Clinical Results With its anti-PD1 OSE-279 in Advanced Solid Tumors - Vimarsana News

OSE Immunotherapeutics Presents First Positive Clinical Results With its anti-PD1 OSE-279 in Advanced Solid Tumors

Published: October 16, 2023

NANTES, France, October 16, 2023--Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented the first Phase 1/2 positive clinical results with high affinity anti-PD1 monoclonal antibody OSE-279 in advanced solid tumors at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held in Boston, MA (October 11 – 15, 2023 - Abstract number 35371, Poster C063).

Source: yahoo.com
Related Topics:
United StatesNicolas PoirierSilvia ComisInternational Conference On MolecularHead Of Clinical DevelopmentVeloxis Pharmaceuticals IncBoehringer IngelheimRegulatory AffairsNantes University HospitalRegulatory NewsMolecular TargetsCancer TherapeuticsClinical DevelopmentDisease Control RateMaximum Tolerated DoseNon Small Cell Lung CancerUlcerative ColitisVeloxis PharmaceuticalsUniversal Registration DocumentMonoclonal AntibodySolid Tumors
OSE Immunotherapeutics SA: OSE Immunotherapeutics Presents Clinical Abstracts on Tedopi at the ASCO 2023 Annual Meeting - Vimarsana News

OSE Immunotherapeutics SA: OSE Immunotherapeutics Presents Clinical Abstracts on Tedopi at the ASCO 2023 Annual Meeting

Published: June 6, 2023

Tedopi is the Company's Most Advanced Product in Clinical Development ATALANTE-1, a Phase 3 clinical trial with positive results comparing Tedopi to chemotherapy in non-small cell lung cancer

Source: finanznachrichten.de
Related Topics:
Mecklenburg VorpommernUnited StatesFrance GeneralStefan KlotterNicolas PoirierFlorence PortejoieSilvia ComisInstitut Gustave RoussyGustave RoussyBenjamin BesseAlexandra LearyBoehringer IngelheimWorld Cancer Research Fund InternationalAmerican Society Of Clinical OncologyMerck Co IncSaclay UniversityMerck Sharp Dohme CorpNantes University HospitalHead Of Clinical DevelopmentCompany Most Advanced Product In Clinical DevelopmentVeloxis Pharmaceuticals IncMost Advanced ProductClinical OncologyAnnual MeetingPrincipal Investigator
OSE Immunotherapeutics Strengthens Leadership Team with the Appointment of Laurence de Schoulepnikoff as Chief Business Officer - Vimarsana News

OSE Immunotherapeutics Strengthens Leadership Team with the Appointment of Laurence de Schoulepnikoff as Chief Business Officer

Published: December 20, 2021

In Addition, Three Senior Executives Will Reinforce the Company’s Drug Development Engine ...

Source: marketscreener.com
Related Topics:
Silvia ComisSanofi EvotecAlexis PeyrolesDominique CostantiniLinda LebonToulouse UniversityBusiness Development At NovartisEuropean Head Of Early Products Medical AffairsBoehringer IngelheimSciences AggregationPfizer Animal HealthCompany As Head Of Clinical DevelopmentFerring InternationalBono As Senior Strategic Development DirectorNantes University HospitalAlliance ManagementPavie UniversitySchool Of ManagementSwiss Healthcare Licensing GroupVoisin Consulting Life SciencesUniversity In MolecularBusiness DevelopmentRegulatory NewsLaurence De SchoulepnikoffChief Business Officer